Linked Life Data

21850213

Source:http://linkedlifedata.com/resource/pubmed/id/21850213

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21850213rdf:typepubmed:Citationlld:pubmed
pubmed-article:21850213lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0221102lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0311400lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0052350lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0243144lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C0449822lld:lifeskim
pubmed-article:21850213lifeskim:mentionsumls-concept:C1685100lld:lifeskim
pubmed-article:21850213pubmed:dateCreated2011-8-18lld:pubmed
pubmed-article:21850213pubmed:abstractTextPurpose: The purpose of this study was to demonstrate the valence of cyclic RGD peptides, P-RGD (PEG(4)-c(RGDfK): PEG(4) = 15-amino-4,710,13-tetraoxapentadecanoic acid), P-RGD(2) (PEG(4)-E[c(RGDfK)](2), 2P-RGD(4) (E{PEG(4)-E[c(RGDfK)](2)}(2), 2P4G-RGD(4) (E{PEG(4)-E[G(3)-c(RGDfK)](2)}(2): G(3) = Gly-Gly-Gly) and 6P-RGD(4) (E{PEG(4)-E[PEG(4)-c(RGDfK)](2)}(2)) in binding to integrin ?(v)?(3), and to assess the impact of peptide and linker multiplicity on biodistribution properties, excretion kinetics and metabolic stability of their corresponding (111)In radiotracers.Methods: Five new RGD peptide conjugates (DOTA-P-RGD (DOTA =1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid), DOTA-P-RGD(2), DOTA-2P-RGD(4), DOTA-2P4G-RGD(4), DOTA-6P-RGD(4)), and their (111)In complexes were prepared. The integrin ?(v)?(3) binding affinity of cyclic RGD conjugates were determined by a competitive displacement assay against (125)I-c(RGDyK) bound to U87MG human glioma cells. Biodistribution, planar imaging and metabolism studies were performed in athymic nude mice bearing U87MG human glioma xenografts.Results: The integrin ?(v)?(3) binding affinity of RGD conjugates follows the order of: DOTA-6P-RGD(4) (IC(50) = 0.3 ± 0.1 nM) ~ DOTA-2P4G-RGD(4) (IC(50) = 0.2 ± 0.1 nM) ~ DOTA-2P-RGD(4) (IC(50) = 0.5 ± 0.1 nM) > DOTA-3P-RGD(2) (DOTA-PEG(4)-E[PEG(4)-c(RGDfK)](2): IC(50) = 1.5 ± 0.2 nM) > DOTA-P-RGD(2) (IC(50) = 5.0 ± 1.0 nM) >> DOTA-P-RGD (IC(50) = 44.3 ± 3.5 nM) ~ c(RGDfK) (IC(50) = 49.9 ± 5.5 nM) >> DOTA-6P-RGK(4) (IC(50) = 437 ± 35 nM). The fact that DOTA-6P-RGK(4) had much lower integrin ?(v)?(3) binding affinity than DOTA-6P-RGD(4) suggests that the binding of DOTA-6P-RGD(4) to integrin ?(v)?(3) is RGD-specific. This conclusion is consistent with the lower tumor uptake for (111)In(DOTA-6P-RGK(4)) than that for (111)In(DOTA-6P-RGD(4)). It was also found that the G(3) and PEG(4) linkers between RGD motifs have a significant impact on the integrin ?(v)?(3)-targeting capability, biodistribution characteristics, excretion kinetics and metabolic stability of (111)In-labeled cyclic RGD peptides.Conclusion: On the basis of their integrin ?(v)?(3) binding affinity and tumor uptake of their corresponding (111)In radiotracers, it was conclude that 2P-RGD(4), 2P4G-RGD(4) and 6P-RGD(4) are most likely bivalent in binding to integrin ?(v)?(3), and extra RGD motifs might contribute to the long tumor retention times of (111)In(DOTA-2P-RGD(4)),( 111)In(DOTA-2P4G-RGD(4)) and (111)In(DOTA-6P-RGD(4)) than that of (111)In(DOTA-3P-RGD(3)) at 72 h p.i. Among the (111)In-labeled cyclic RGD tetramers evaluated in the glioma model, (111)In(DOTA-2P4G-RGD(4)) has very high tumor uptake with the best tumor/kidney and tumor/liver ratios, suggesting that (90)Y(DOTA-2P4G-RGD(4)) and (177)Lu(DOTA-2P4G-RGD(4)) might have the potential for targeted radiotherapy of integrin ?(v)?(3)-positive tumors.lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:languageenglld:pubmed
pubmed-article:21850213pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21850213pubmed:statusPubMed-not-MEDLINElld:pubmed
pubmed-article:21850213pubmed:issn1838-7640lld:pubmed
pubmed-article:21850213pubmed:authorpubmed-author:BestP VPVlld:pubmed
pubmed-article:21850213pubmed:authorpubmed-author:LiuShuangSlld:pubmed
pubmed-article:21850213pubmed:authorpubmed-author:WangFanFlld:pubmed
pubmed-article:21850213pubmed:authorpubmed-author:ZhouYangYlld:pubmed
pubmed-article:21850213pubmed:authorpubmed-author:ChakrabortySu...lld:pubmed
pubmed-article:21850213pubmed:authorpubmed-author:KimYoung-Seun...lld:pubmed
pubmed-article:21850213pubmed:authorpubmed-author:ShiJiyunJlld:pubmed
pubmed-article:21850213pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21850213pubmed:volume1lld:pubmed
pubmed-article:21850213pubmed:ownerNLMlld:pubmed
pubmed-article:21850213pubmed:authorsCompleteYlld:pubmed
pubmed-article:21850213pubmed:pagination322-40lld:pubmed
pubmed-article:21850213pubmed:year2011lld:pubmed
pubmed-article:21850213pubmed:articleTitleEvaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability.lld:pubmed
pubmed-article:21850213pubmed:affiliation1. School of Health Sciences, Purdue University, IN 47907, USA.lld:pubmed
pubmed-article:21850213pubmed:publicationTypeJournal Articlelld:pubmed